Clinical Insights: June 4, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Olumiant® (baricitinib) – June 1, 2018 – Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the 2-mg…
Discover Program Compliance with RxStrategies
At RxStrategies, we work with Covered Entities (CE) to create customized 340B solutions that proactively position CEs to maintain compliance implementing internal processes, controls and protocols for internal audits and review purposes. Our 340B CompliancePlus solution also promotes the benefits of engaging broad-based CE teams in program compliance and support and provides them with tools to…
Clinical Insights: May 23, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Doptelet® (avatrombopag) – May 21, 2018 – The Food and Drug Administration approved avatrombopag (Doptelet®, AkaRx Inc.) for thrombocytopenia in adults with chronic liver disease scheduled to…
Clinical Insights: May 16, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Retacrit® (epoetin alfa-epbx) – New Biosimilar Drug Approval – May 15, 2018 – U.S. Food and Drug Administration approved Retacrit®(epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin…
Comprehensive Solutions for Your FQHC
According to NACHC, “community health centers serve as the primary medical home for more than 27 million people in 10,400 rural and urban communities across America.” Just one form of Federally Qualified Health Centers (FQHC), community health centers receive funds from the HRSA Health Center Program to support and serve underserved areas (HRSA). The number…
Clinical Insights: May 9, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Plenvu® (polyethylene glycol 3350 with electrolytes) – May 7, 2018 – Salix Pharmaceuticals, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Plenvu®…
Clinical Insights: May 1, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval JynarqueTM (tolvaptan) – April 24, 2018 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved JynarqueTM (tolvaptan) as…
Clinical Insights: April 23, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Crysvita® (burosumab-twza) – New Orphan Drug Approval – April 17, 2018 – U.S. Food and Drug Administration approved Crysvita® (burosumab-twza), the first drug approved to treat adults…
Clinical Insights: April 16, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval No new updates. New Formulation Approval Afinitor Disperz® (everolimus) – New Formulation and Indication Approval – April 10, 2018 – On April 10, 2018, the Food…
Clinical Insights: April 3, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval SymfiTM (efavirenz, lamivudine and tenofovir disoproxil fumarate) – March 22, 2018 – Mylan N.V. announced that it will introduce in the U.S. a third cost-saving HIV…
Clinical Insights: March 23, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval IlumyaTM (tildrakizumab-asmn) – New Drug Approval – March 21, 2018 – Sun Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved…
Clinical Insights: February 13, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Biktarvy® (bictegravir, emtricitabine and tenofovir alafenamide) – February 7, 2018 – Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy®…